Literature DB >> 21637966

Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma.

Jaudah Al-Maghrabi1, Mahmoud Al-Ahwal, Abdelbaset Buhmeida, Kari Syrjänen, Abdulrahman Sibyani, Eman Emam, Ayman Ghanim, Mohmmad Al-Qahtani.   

Abstract

BACKGROUND: Recent studies suggest that aberrations in cell cycle checkpoint controllers are a common feature in human malignancies and predict prognosis independent of stage.
OBJECTIVES: This study correlated two cell cycle regulators (p27 and p21) with clinical and pathological variables in colorectal cancer (CRC) patients to assess their role as prognostic factors. PATIENTS AND METHODS: A series of 65 CRC patients were analyzed for p27 and p21 expression in their tumors using immunohistochemistry.
RESULTS: Forty-six percent of tumors showed positive nuclear p27 expression, whereas 72% of cases were completely p21 negative. There were no significant correlations between p27 and p21 expression and gender, age, lymph node involvement, stage, and grade. However, p27 (but not p21) expression revealed highly significant correlation with tumor location (p < 0.01), depth of invasion (p < 0.03), and lympho-vascular invasion (p < 0.02). Tumors with high p27 expression showed a higher recurrence rate than tumors with no expression (p < 0.03). In Kaplan-Meier survival analysis, there was a significant (p = 0.046) difference in disease-free survival (DFS) between p27-positive and p27-negative tumors in favor of the latter. p21 did not show any predictive value of DFS (p < 0.7). Neither p27 nor p21 did predict disease-specific survival (DSS) in Kaplan-Meier analysis, but DSS time was much shorter for p27-positive tumors. In multivariate (Cox) model, p27 lost its value as independent predictor of DFS, and none of the covariates were independent predictors of DSS.
CONCLUSION: p27 expression seems to be more powerful than p21 expression in providing useful prognostic information in CRC, particularly in predicting the patients at high risk for recurrent disease. Larger cohort and longer follow-up are needed to fully elucidate the value of p27 (and p21) as independent predictors of disease outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21637966     DOI: 10.1007/s12029-011-9292-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  44 in total

1.  Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.

Authors:  W A Bleeker; V M Hayes; A Karrenbeld; R M Hofstra; J Hermans; C C Buys; J T Plukker
Journal:  Am J Gastroenterol       Date:  2000-10       Impact factor: 10.864

2.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

3.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

4.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis.

Authors:  Tzeela Cohen; Diana Prus; Jinru Shia; Bassam Abu-Wasel; Meir G Pinto; Herbert R Freund; Alexander Stojadinovic; Anna Grakov; Tamar Peretz; Aviram Nissan
Journal:  J Surg Oncol       Date:  2008-04-01       Impact factor: 3.454

6.  Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma.

Authors:  Li Chen; Daiyue Yuan; Gui-lan Wang; You Wang; Yuan-Yuan Wu; Jianwei Zhu
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

Review 7.  Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?

Authors:  F Graziano; S Cascinu
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

8.  MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases.

Authors:  Riyad Bendardaf; Abdelbaset Buhmeida; Raija Ristamäki; Kari Syrjänen; Seppo Pyrhönen
Journal:  Scand J Gastroenterol       Date:  2007-12       Impact factor: 2.423

9.  DNA image cytometry predicts disease outcome in stage II colorectal carcinoma.

Authors:  A Buhmeida; M Hilska; A Elzagheid; M Laato; Y Collan; K Syrjänen; S Pyrhönen
Journal:  Anticancer Res       Date:  2009-01       Impact factor: 2.480

View more
  10 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Authors:  A R Garcia-Rendueles; J S Rodrigues; M E R Garcia-Rendueles; M Suarez-Fariña; S Perez-Romero; F Barreiro; I Bernabeu; J Rodriguez-Garcia; L Fugazzola; T Sakai; F Liu; J Cameselle-Teijeiro; S B Bravo; C V Alvarez
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

3.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20

Review 4.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

5.  Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy.

Authors:  Qiong Jia; Fang Yang; Wei Huang; Yao Zhang; Binghao Bao; Ke Li; Fuxiang Wei; Cunyu Zhang; Haibo Jia
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

6.  Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.

Authors:  Amani A Mahbub; Akhmed Aslam; Mohamed E Elzubier; Mohamed El-Boshy; Abdelghany H Abdelghany; Jawwad Ahmad; Shakir Idris; Riyad Almaimani; Aiman Alsaegh; Mahmoud Zaki El-Readi; Mohammed A Baghdadi; Bassem Refaat
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-03       Impact factor: 6.055

7.  Concomitant depletion of PTEN and p27 and overexpression of cyclin D1 may predict a worse prognosis for patients with post-operative stage II and III colorectal cancer.

Authors:  Jing Li; Lin-Lin Yin; Ke-Li Su; Gang-Feng Zhang; Jing Wang
Journal:  Oncol Lett       Date:  2014-07-14       Impact factor: 2.967

8.  TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway.

Authors:  Shu-Yang Wang; Ke Gao; Dan-Ling Deng; Juan-Juan Cai; Zhi-Yuan Xiao; Liu-Qing He; Hong-Li Jiao; Ya-Ping Ye; Run-Wei Yang; Ting-Ting Li; Li Liang; Wen-Ting Liao; Yan-Qing Ding
Journal:  Oncotarget       Date:  2016-01-19

9.  Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data.

Authors:  Dan-Dan Xiong; Rong-Quan He; Ai-Hua Lan; Wen-Jie Chen; Yi-Huan Luo; Zhi-Hua Ye; Jie Ma; Gang Chen; Yi-Wu Dang
Journal:  Oncotarget       Date:  2018-01-23

10.  In Vivo and In Vitro Enhanced Tumoricidal Effects of Metformin, Active Vitamin D3, and 5-Fluorouracil Triple Therapy against Colon Cancer by Modulating the PI3K/Akt/PTEN/mTOR Network.

Authors:  Riyad Adnan Almaimani; Akhmed Aslam; Jawwad Ahmad; Mahmoud Zaki El-Readi; Mohamed E El-Boshy; Abdelghany H Abdelghany; Shakir Idris; Mai Alhadrami; Mohammad Althubiti; Hussain A Almasmoum; Mazen M Ghaith; Mohamed E Elzubeir; Safaa Yehia Eid; Bassem Refaat
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.